GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, email@example.com
Index / US Biomax / Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed / Product Detail : LM482 Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
#LM482 Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
Product name : Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
Catalog number : LM482
Supplier name : US Biomax
Data sheet: Ask more or other datasheet now !
About this Product :Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed antibody storage GENTAUR recommends for long therm storage to freeze at -24 C. For short time storage up to 30 days we suggest fridge storage at 1 to 10 C. Prevent multiple freeze taw cycles of Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed.
Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed storing antibdies for longer storage periods of the Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed we recommend - 21C or lower and for short periods lees than 1 month we suggest +5C fridge temperatures.
More Details about
|Microarray Panel:||Myeloma, lymphoma and normal tissue microarray, containing 10 cases of each myeloma, Hodgkin's lymphoma and large B-cell lymphoma, 8 Burkett's lymphoma, 3 each of follicular Non-Hodgkin's lymphoma and T-cell lymphoma, 4 normal lymph node tissue, single core per case|
|Layout:||8 cols × 6 rows|
|Core Diameter:||2 mm|
|Quality Control:||Anti-Actin confirmed|
|Applications:||Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.|
|Notes:||Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.|
*Tissue Microarray Slide Types:
- Unstained: unstained paraffin tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Contact us about this product :
Our team will respond you as soon as possible !
We have also other products like : Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
firstname.lastname@example.org | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1019: FAS pathway and Stress induction of HSP regulation
WP1062: Regulation of Actin Cytoskeleton
WP1138: FAS pathway and Stress induction of HSP regulation
WP1178: Regulation of Actin Cytoskeleton
WP1380: Regulation of Actin Cytoskeleton
WP1963: The effect of Glucocorticoids on target gene expression
WP2272: Pathogenic Escherichia coli infection
WP2292: Chemokine signaling pathway
WP314: FAS pathway and Stress induction of HSP regulation
WP351: Regulation of Actin Cytoskeleton
WP51: Regulation of Actin Cytoskeleton
WP511: FAS pathway and Stress induction of HSP regulation
WP523: Regulation of Actin Cytoskeleton
WP571: FAS pathway and Stress induction of HSP regulation
WP788: FAS pathway and Stress induction of HSP regulation
WP824: Regulation of Actin Cytoskeleton
WP89: FAS pathway and Stress induction of HSP regulation
WP902: FAS pathway and Stress induction of HSP regulation
WP944: Regulation of Actin Cytoskeleton
Related Genes :
[FGFR3 JTK4] Fibroblast growth factor receptor 3 (FGFR-3) (EC 126.96.36.199) (CD antigen CD333)
[Adam9 Kiaa0021 Mdc9 Mltng] Disintegrin and metalloproteinase domain-containing protein 9 (ADAM 9) (EC 3.4.24.-) (Meltrin-gamma) (Metalloprotease/disintegrin/cysteine-rich protein 9) (Myeloma cell metalloproteinase)
[XBP1 TREB5 XBP2] X-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5) [Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal form]
[NR3C1 GRL] Glucocorticoid receptor (GR) (Nuclear receptor subfamily 3 group C member 1)
[Xbp1 Treb5] X-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5) [Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal form]
[CCND1 BCL1 PRAD1] G1/S-specific cyclin-D1 (B-cell lymphoma 1 protein) (BCL-1) (BCL-1 oncogene) (PRAD1 oncogene)
[MET] Hepatocyte growth factor receptor (HGF receptor) (EC 188.8.131.52) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met)
[MTOR FRAP FRAP1 FRAP2 RAFT1 RAPT1] Serine/threonine-protein kinase mTOR (EC 184.108.40.206) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP12 target 1) (Rapamycin target protein 1)
[PIK3R1 GRB1] Phosphatidylinositol 3-kinase regulatory subunit alpha (PI3-kinase regulatory subunit alpha) (PI3K regulatory subunit alpha) (PtdIns-3-kinase regulatory subunit alpha) (Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha) (PI3-kinase subunit p85-alpha) (PtdIns-3-kinase regulatory subunit p85-alpha)
[LYN JTK8] Tyrosine-protein kinase Lyn (EC 220.127.116.11) (Lck/Yes-related novel protein tyrosine kinase) (V-yes-1 Yamaguchi sarcoma viral related oncogene homolog) (p53Lyn) (p56Lyn)
[LIG4] DNA ligase 4 (EC 18.104.22.168) (DNA ligase IV) (Polydeoxyribonucleotide synthase [ATP] 4)
[IL6ST] Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
[MUC1 PUM] Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Cancer antigen 15-3) (CA 15-3) (Carcinoma-associated mucin) (Episialin) (H23AG) (Krebs von den Lungen-6) (KL-6) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associated mucin) (CD antigen CD227) [Cleaved into: Mucin-1 subunit alpha (MUC1-NT) (MUC1-alpha); Mucin-1 subunit beta (MUC1-beta) (MUC1-CT)]
[Ighm Igh-6] Ig mu chain C region
[MICA PERB11.1] MHC class I polypeptide-related sequence A (MIC-A)
[EIF4E EIF4EL1 EIF4F] Eukaryotic translation initiation factor 4E (eIF-4E) (eIF4E) (eIF-4F 25 kDa subunit) (mRNA cap-binding protein)
[BST2] Bone marrow stromal antigen 2 (BST-2) (HM1.24 antigen) (Tetherin) (CD antigen CD317)
[Kmt2c Mll3] Histone-lysine N-methyltransferase 2C (Lysine N-methyltransferase 2C) (EC 22.214.171.124) (Myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog)
[NUP153] Nuclear pore complex protein Nup153 (153 kDa nucleoporin) (Nucleoporin Nup153)
[HPSE HEP HPA HPA1 HPR1 HPSE1 HSE1] Heparanase (EC 126.96.36.199) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit]
[IFNAR2 IFNABR IFNARB] Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2)
[IGHA1] Ig alpha-1 chain C region
[MAF] Transcription factor Maf (Proto-oncogene c-Maf) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog)
[RPS6KA3 ISPK1 MAPKAPK1B RSK2] Ribosomal protein S6 kinase alpha-3 (S6K-alpha-3) (EC 188.8.131.52) (90 kDa ribosomal protein S6 kinase 3) (p90-RSK 3) (p90RSK3) (Insulin-stimulated protein kinase 1) (ISPK-1) (MAP kinase-activated protein kinase 1b) (MAPK-activated protein kinase 1b) (MAPKAP kinase 1b) (MAPKAPK-1b) (Ribosomal S6 kinase 2) (RSK-2) (pp90RSK2)
[Adam15 Mdc15] Disintegrin and metalloproteinase domain-containing protein 15 (ADAM 15) (EC 3.4.24.-) (AD56) (Metalloprotease RGD disintegrin protein) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 15) (MDC-15) (Metargidin)
[Dbnl Abp1 Sh3p7] Drebrin-like protein (Actin-binding protein 1) (SH3 domain-containing protein 7)
[COPS5 CSN5 JAB1] COP9 signalosome complex subunit 5 (SGN5) (Signalosome subunit 5) (EC 3.4.-.-) (Jun activation domain-binding protein 1)
[BLZF1 JEM1] Golgin-45 (Basic leucine zipper nuclear factor 1) (JEM-1) (p45 basic leucine-zipper nuclear factor)
[CASP10 MCH4] Caspase-10 (CASP-10) (EC 184.108.40.206) (Apoptotic protease Mch-4) (FAS-associated death domain protein interleukin-1B-converting enzyme 2) (FLICE2) (ICE-like apoptotic protease 4) [Cleaved into: Caspase-10 subunit p23/17; Caspase-10 subunit p12]
[CXCL11 ITAC SCYB11 SCYB9B] C-X-C motif chemokine 11 (Beta-R1) (H174) (Interferon gamma-inducible protein 9) (IP-9) (Interferon-inducible T-cell alpha chemoattractant) (I-TAC) (Small-inducible cytokine B11)
 Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
 Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
 Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
 New investigational drugs with single-agent activity in multiple myeloma.
 Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
 Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to Bone.
 BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
 Incidental detection of abnormal (99m)Tc-sestamibi uptake in the sternum and ribcage from multiple myeloma by SPECT myocardial perfusion imaging.
 Multiple myeloma, immunotherapy and minimal residual disease.
 Detection of Interleukin-1β and Interleukin-6 in Human Multiple Myeloma by Fluorescent in situ Hybridization.
Enter catalog number :